Covenant Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-28,343
| Closed | -$3.9M | – | 147 |
|
|
2024
Q2 | $3.9M | Buy |
28,343
+37
| +0.1% | +$5.09K | 0.62% | 38 |
|
|
2024
Q1 | $3.9M | Buy |
28,306
+535
| +2% | +$73.8K | 0.64% | 36 |
|
|
2023
Q4 | $3.66M | Sell |
27,771
-2,280
| -8% | -$300K | 0.66% | 34 |
|
|
2023
Q3 | $3.38M | Buy |
30,051
+11,628
| +63% | +$1.31M | 0.89% | 35 |
|
|
2023
Q2 | $1.74M | Sell |
18,423
-85
| -0.5% | -$8.02K | 0.44% | 58 |
|
|
2023
Q1 | $1.87M | Buy |
+18,508
| New | +$1.87M | 0.45% | 55 |
|